AI Article Synopsis

  • Recent genetic studies have enhanced understanding of GABA(A) receptor subtypes, prompting the creation of new benzodiazepine-like drugs that are selective and less active at alpha(1) subunit receptors.
  • Four new ligands were tested for their effects on behavior in rats to evaluate sedative, anxiolytic, and amnesic properties associated with benzodiazepines.
  • Results showed that while these ligands generally had low activity at alpha(1) receptors, two (SH-053-2'N and SH-053-S-CH3-2'F) demonstrated anxiolytic effects, and all ligands avoided inducing memory impairment, indicating a specific activity profile related to GABA(A) receptor subtypes.

Article Abstract

Over the last years, genetic studies have greatly improved our knowledge on the receptor subtypes mediating various pharmacological effects of positive allosteric modulators at GABA(A) receptors. This stimulated the development of new benzodiazepine (BZ)-like ligands, especially those inactive/low-active at GABA(A) receptors containing the alpha(1) subunit, with the aim of generating more selective drugs. Hereby, the affinity and efficacy of four recently synthesized BZ site ligands: SH-053-2'N, SH-053-S-CH3-2'F, SH-053-R-CH3-2'F and JY-XHe-053 were assessed. They were also studied in behavioral tests of spontaneous locomotor activity, elevated plus maze, and water maze in rats, which are considered predictive of, respectively, the sedative, anxiolytic, and amnesic influence of BZs. The novel ligands had moderately low to low affinity and mild to partial agonistic efficacy at GABA(A) receptors containing the alpha(1) subunit, with variable, but more pronounced efficacy at other BZ-sensitive binding sites. While presumably alpha(1) receptor-mediated sedative effects of GABA(A) modulation were not fully eliminated with any of the ligands tested, only SH-053-2'N and SH-053-S-CH3-2'F, both dosed at 30 mg/kg, exerted anxiolytic effects. The lack of clear anxiolytic-like activity of JY-XHe-053, despite its efficacy at alpha(2)- and alpha(3)-GABA(A) receptors, may have been partly connected with its preferential affinity at alpha(5)-GABA(A) receptors coupled with weak agonist activity at alpha(1)-containing subtypes. The memory impairment in water-maze experiments, generally reported with BZ site agonists, was completely circumvented with all four ligands. The results suggest that a substantial amount of activity at alpha(1) GABA(A) receptors is needed for affecting spatial learning and memory impairments, while much weaker activity at alpha(1)- and alpha(5)-GABA(A) receptors is sufficient for eliciting sedation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859624PMC
http://dx.doi.org/10.1016/j.pnpbp.2010.01.004DOI Listing

Publication Analysis

Top Keywords

gabaa receptors
20
positive allosteric
8
allosteric modulators
8
modulators gabaa
8
receptors
8
activity alpha1
8
receptors alpha1
8
alpha1 subunit
8
sh-053-2'n sh-053-s-ch3-2'f
8
alpha5-gabaa receptors
8

Similar Publications

Gene Deficiency of δ Subunit-Containing GABA Receptor in mPFC Lead Learning and Memory Impairment in Mice.

Neurochem Res

January 2025

Laboratory of Chinese Medicine Brain Science, Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.

Maintaining GABAergic inhibition within physiological limits in the medial prefrontal cortex (mPFC) is critical for working memory. While synaptic GABAR typically mediate the primary component of mPFC inhibition, the role of extrasynaptic δ-GABAR in working memory remains unclear. To investigate this, we used fiber photometry to examine the effects of δ-GABAR in freely moving mice.

View Article and Find Full Text PDF

Aims: N-Demethylsinomenine (NDSM) demonstrates good analgesic efficacy in preclinical pain models. However, how NDSM exerts analgesic actions remains unknown.

Methods: We examined the analgesic effects of NDSM using both pain-evoked and pain-suppressed behavioral assays in two persistent pain models.

View Article and Find Full Text PDF

Effects of ketamine and propofol on muscarinic plateau potentials in rat neocortical pyramidal cells.

PLoS One

January 2025

Department of Molecular Medicine, Brain Signalling Laboratory, Institute of Basic Medical Sciences, Section for Physiology, University of Oslo, Oslo, Norway.

Propofol and ketamine are widely used general anaesthetics, but have different effects on consciousness: propofol gives a deeply unconscious state, with little or no dream reports, whereas vivid dreams are often reported after ketamine anaesthesia. Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist, while propofol is a γ-aminobutyric-acid (GABAA) receptor positive allosteric modulator, but these mechanisms do not fully explain how these drugs alter consciousness. Most previous in vitro studies of cellular mechanisms of anaesthetics have used brain slices or neurons in a nearly "comatose" state, because no "arousing" neuromodulators were added.

View Article and Find Full Text PDF

Gastrointestinal dysfunction is a severe and common complication in diabetic patients. Some evidence shows that gamma-aminobutyric acid (GABA) and glutamate contribute to diabetic gastrointestinal abnormalities. Therefore, we examined the impact of prolonged treatment with insulin and magnesium supplements on the expression pattern of GABA type A (GABA-A), GABA-B, and N-methyl-D-aspartate (NMDA) glutamate receptors as well as nitric oxide synthase 1 (NOS-1) in the stomach of type 2 diabetic rats.

View Article and Find Full Text PDF

Cannabichromene from full-spectrum hemp extract exerts acute anti-seizure effects through allosteric activation of GABA receptors.

Fundam Res

November 2024

State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.

The approval of Epidiolex, an anti-epileptic drug containing cannabidiol (CBD) as its active component, has brought hope to patients with refractory epilepsy. However, the anti-seizure effect of full-spectrum hemp extract (HE), a CBD-enriched hemp oil, remains unclear. In this study, we investigated the anti-seizure effect of HE using drug-induced seizure models.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!